Clinical Study

A Randomized Phase III Trial Of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles Of Docetaxel Plus Cyclophosphamide Or Four Cycles Of Doxorub

Posted Date: May 15, 2019

  • Investigator: Elizabeth Shaughnessy
  • Specialties:
  • Type of Study: Drug

This study will determine if adding a targed therapy to standard treatment with chemotherapy for early stage, HER2-low breast cancer, will prevent breast cancer from returning. Participation in this study will last for 10 years. Chemotherapy will take 4-6 months. About 3, 260 women will take part in

Criteria:

Eligible Patients Must Have Early Stage Breast Cancer That Has Been Removed By Surgery

Keywords:

B-47, Breast Cancer, Her2, High Risk, Node Negative

For More Information:

Uc Cancer Institute
513-584-7698
kastla@ucmail.uc.edu


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.